These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20195035)

  • 1. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population.
    Taneja R; Malik P; Sharma M; Agarwal MC
    Indian J Ophthalmol; 2010; 58(2):125-30. PubMed ID: 20195035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal abnormalities in β-thalassemia major.
    Bhoiwala DL; Dunaief JL
    Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
    Gomber S; Dabas A; Bagmar S; Madhu SV
    J Pediatr Hematol Oncol; 2018 Jan; 40(1):56-59. PubMed ID: 29200160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular abnormalities in multi-transfused beta-thalassemia patients.
    Jafari R; Heydarian S; Karami H; Shektaei MM; Dailami KN; Amiri AA; Rezaee MR; Far AA
    Indian J Ophthalmol; 2015 Sep; 63(9):710-5. PubMed ID: 26632126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Thalassemia and ocular implications: a systematic review.
    Liaska A; Petrou P; Georgakopoulos CD; Diamanti R; Papaconstantinou D; Kanakis MG; Georgalas I
    BMC Ophthalmol; 2016 Jul; 16():102. PubMed ID: 27390837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
    Fischer R; Longo F; Nielsen P; Engelhardt R; Hider RC; Piga A
    Br J Haematol; 2003 Jun; 121(6):938-48. PubMed ID: 12786807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular findings in beta-thalassemia.
    Sorcinelli R; Sitzia A; Figus A; Lai ME
    Metab Pediatr Syst Ophthalmol (1985); 1990; 13(1):23-5. PubMed ID: 2370833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: our experience.
    Jethani J; Marwah K; ; Patel S; Shah B
    Indian J Ophthalmol; 2010; 58(5):451-2. PubMed ID: 20689215
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined therapy with deferiprone and desferrioxamine.
    Wonke B; Wright C; Hoffbrand AV
    Br J Haematol; 1998 Nov; 103(2):361-4. PubMed ID: 9827905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
    Huang YC; Chang JS; Wu KH; Peng CT
    Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
    Porcu M; Landis N; Salis S; Corda M; Orrù P; Serra E; Usai B; Matta G; Galanello R
    Eur J Heart Fail; 2007 Mar; 9(3):320-2. PubMed ID: 17029959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
    Hagag AA; Elfaragy MS; Elrifaey SM; Abd El-Lateef AE
    Infect Disord Drug Targets; 2015; 15(3):189-95. PubMed ID: 26239735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.